Cargando…
初始易瑞沙治疗有效的晚期肺腺癌二次使用易瑞沙的疗效分析
BACKGROUND AND OBJECTIVE: Gefitinib is an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that has been widely used for the treatment of non-small cell lung cancer (NSCLC). It is most effective in women, as well as in patients who have never smoked, have pulmonary adenocarcinom...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999970/ https://www.ncbi.nlm.nih.gov/pubmed/22237124 http://dx.doi.org/10.3779/j.issn.1009-3419.2012.01.09 |
Ejemplares similares
-
中国易瑞沙扩大用药项目中晚期非小细胞肺癌长期生存患者的研究
Publicado: (2012) -
长春瑞滨联合奥沙利铂对比长春瑞滨联合顺铂治疗中晚期非小细胞肺癌的系统评价
Publicado: (2010) -
盐酸埃克替尼一线治疗晚期肺腺癌的临床疗效观察
Publicado: (2013) -
BAG家族基因表达与肺腺癌易感性的相关性研究
Publicado: (2010) -
厄洛替尼100 mg/天治疗化疗后进展的晚期肺腺癌的临床研究
Publicado: (2011)